Blinatumoab公司
医学
美罗华
单克隆抗体
奥图穆马
CD20
卡奇霉素
化学免疫疗法
奥比努图库单抗
阿勒姆图祖马
急性淋巴细胞白血病
免疫学
化疗
免疫结合物
人口
抗原
白血病
肿瘤科
内科学
抗体
CD19
淋巴细胞白血病
环境卫生
作者
Elias Jabbour,Susan O’Brien,Farhad Ravandi,Hagop M. Kantarjian
出处
期刊:Blood
[American Society of Hematology]
日期:2015-05-21
卷期号:125 (26): 4010-4016
被引量:144
标识
DOI:10.1182/blood-2014-08-596403
摘要
Abstract With modern intensive combination polychemotherapy, the complete response (CR) rate in adults with acute lymphoblastic leukemia (ALL) is 80% to 90%, and the cure rate is 40% to 50%. Hence, there is a need to develop effective salvage therapies and combine novel agents with standard effective chemotherapy. ALL leukemic cells express several surface antigens amenable to target therapies, including CD20, CD22, and CD19. Monoclonal antibodies target these leukemic surface antigens selectively and minimize off-target toxicity. When added to frontline chemotherapy, rituximab, an antibody directed against CD20, increases cure rates of adults with Burkitt leukemia from 40% to 80% and those with pre-B ALL from 35% to 50%. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has resulted in marrow CR rates of 55% and a median survival of 6 to 7 months when given to patients with refractory-relapsed ALL. Blinatumomab, a biallelic T cell engaging the CD3-CD19 monoclonal antibody, also resulted in overall response rates of 40% to 50% and a median survival of 6.5 months in a similar refractory-relapsed population. Other promising monoclonal antibodies targeting CD20 (ofatumumab and obinutuzumab) or CD19 or CD20 and bound to different cytotoxins or immunotoxins are under development. Combined modalities of chemotherapy and the novel monoclonal antibodies are under investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI